Latest Articles
-
What To Expect From Abbott In Q1?
Abbott Labs (NYSE:ABT) is expected to publish its Q1 2019 results on April 17. This note details Trefis’ forecasts for Abbott, as well as some of the key trends we will be watching when the company reports earnings. How have Abbott’s reve...
-
What Are Abbott Laboratories’ Key Sources of Revenue?
Abbott Labs (NYSE:ABT) generates its revenues from Medical Devices, Nutritionals, Diagnostics, and Generic Pharmaceuticals business. Medical Devices is the largest segment, and accounts for more than one-third of the company’s total revenu...
-
Expect Abbott To Continue To See Steady Earnings Growth In The Near Term
Abbott Labs (NYSE:ABT) recently posted its Q4 results, which were in line with our estimates . Medical Devices continued to see steady sales growth, led by electrophysiology, and strong FreeStyle Libre sales. Established Pharmaceutical Products ...
-
What To Watch For In Abbott Labs’ Q4 Earnings
Abbott Labs (NYSE:ABT) is set to report its Q4 2018 earnings on January 23, and we expect the company to post steady growth, primarily led by its Cardiovascular & Neuromodulation, as well as Diagnostics segments. While the Diagnostics busine...
-
How Much Can Abbott’s Share Price Gain If FreeStyle Libre Garners 30% Share of The Blood Glucose Monitoring Market?
Abbott Labs’ (NYSE:ABT) stock price could gain over 10% if its FreeStyle Libre system captures a 30% share of the blood glucose monitoring market by 2020, according to our estimates. FreeStyle Libre has seen strong acceptance in recent qua...
-
Expect Diagnostics And Medical Devices Business To Drive Abbott’s Near Term Earnings Growth
Abbott Labs (NYSE:ABT) has seen strong revenue growth in the recent quarters, primarily led by its Diagnostics business, reflecting the impact of the Alere acquisition, which was completed in Q4 2017. Apart from Diagnostics, the company is also ...
-
What To Watch For In Abbott Labs’ Q3 Earnings
Abbott Labs (NYSE:ABT) is set to report its Q3 2018 earnings on October 17, and we expect the company to post steady growth, led by its Diagnostics and Medical Devices segments. While the Diagnostics business will likely benefit from market shar...
-
Here’s What Will Drive Abbott’s Near Term Revenue Growth
Abbott Labs (NYSE:ABT) generates its revenues from Medical Devices, Nutritionals, Diagnostics, and Generic Pharmaceutical Products. Medical Devices is the largest segment, and accounts for roughly 40% of the company’s total revenues and pr...
-
What Will Drive Abbott Labs’ Near Term Growth
Abbott Labs (NYSE:ABT) has seen strong revenue growth in the recent past, primarily reflecting the impact of acquisitions it made over the last couple of years. The company’s Diagnostics business will likely see a double digit growth for t...
-
Abbott Earnings Preview: Expect Diagnostics To Lead Q2 Earnings Growth
Abbott Labs (NYSE:ABT) is set to report its Q2 2018 earnings on July 18, and we expect the company to post steady growth, led by its Diagnostics and Generic Pharmaceuticals segments. While the Diagnostics business will continue to benefit from A...
-
How Have Abbott’s Revenues And Profits Changed In Recent Years?
Abbott Labs ‘ (NYSE:ABT) revenues have increased by $7.7 billion (net) between 2013-2017. Gross profits also increased by $5.5 billion during the same period. Most of this change was led by the company’s Medical Devices segment, which...
-
Abbott Q1 Preview: Expect Diagnostics Business To Drive Earnings Growth
Abbott Labs (NYSE:ABT) is set to report its Q1 2018 earnings on April 18, and we expect the company to post solid numbers, primarily led by its Diagnostics business, reflecting the benefits of the Alere acquisition. We also expect the company...
-
How Will Abbott Labs Perform In 2018?
We forecast Abbott Labs (NYSE:ABT) to post a double digit revenue growth and adjusted EPS of $2.90 in 2018. We expect the revenue growth to be led by its Diagnostics business, primarily reflecting the gains from the Alere acquisition. 2017 was a ...
-
A Snapshot Of Abbott Labs’ Business
Abbott Labs (NYSE:ABT) struggled to generate significant growth in recent years, which in part prompted the company to make two significant acquisitions. While there was some skepticism in the market initially as the acquisitions impacted the co...
-
How Much Can Abbott’s Stock Move In 2018?
2017 was a good year for Abbott (NYSE:ABT), as the company’s stock gained nearly 50%. The momentum continued in the first month of 2018 as well, as better than expected Q4’17 results triggered the stock movement. It appears that Abbo...
